Mark Salvati

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger, Leora Horn, Leena Gandhi et al. · Journal of Clinical Oncology · 2015 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone

John S. Sack, Kevin Kish, Chihuei Wang et al. · Proceedings of the National Academy of Sciences · 2001 · 485 citations · Full text

Life Sciences, Biochemistry, Endocrinology +17

Drug safety is a barrier to the discovery and development of new androgen receptor antagonists

William R. Foster, Bruce D. Car, Hong Shi et al. · The Prostate · 2010 · 119 citations

Medicine, Oncology, Pharmacology +15

Novel interstrand cross-links induced by the antitumor antibiotic carzinophilin/azinomycin B

Robert W. Armstrong, Mark Salvati, Michael Nguyen · Journal of the American Chemical Society · 1992 · 119 citations

Medicine, Medicinal Chemistry, Pharmacology +6

Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists

Mark Salvati, Aaron Balog, Weifang Shan et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 62 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12